• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tectonic Therapeutic Inc.

    3/20/25 5:07:06 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    S-8 1 d803448ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Tectonic Therapeutic, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-0710585

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    490 Arsenal Way

    Suite 210

    Watertown, MA

      02472
    (Address of Principal Executive Offices)   (Zip Code)

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full titles of the plans)

    Daniel Lochner

    Chief Financial Officer

    490 Arsenal Way

    Suite 210

    Watertown, MA 02472

    (339) 666-3320

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Divakar S. Gupta

    Brandon Fenn

    Minkyu Park

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    (212) 479-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated Filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Tectonic Therapeutic, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange commission (the “Commission”) for the purpose of registering (a) 742,815 shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), issuable to eligible persons under the Registrant’s 2024 Equity Incentive Plan (the “2024 Plan”), pursuant to the provisions of the 2024 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2024 Plan on January 1, 2025 and (b) 148,563 shares of Common Stock issuable to eligible persons under the Registrant’s 2024 Employee Stock Purchase Plan (the “2024 ESPP”), pursuant to the provisions of the 2024 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2024 ESPP on January 1, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    These shares of Common Stock are additional securities of the same class as other securities for which the Registration Statement on Form S-8 was previously filed with the Commission, including any post-effective amendments thereto (File No. 333-281690) (collectively, the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statement are incorporated by reference into this Registration Statement, except that the provisions contained in Part II of such Prior Registration Statement are modified or supplemented, as the case may be, as set forth in this Registration Statement.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

    (a) Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025;

    (b) Current Reports on Form 8-K, which were filed with the Commission on January  30, 2025 and February 3, 2025 (except that, with respect to the foregoing Current Reports, any portions thereof which are furnished and not filed shall not be deemed incorporated by reference); and

    (b) the description of the Registrant’s common stock in the Registrant’s registration statement on Form 8-A filed with the Commission on June 11, 2018, including any amendments or reports filed for the purpose of updating such description, including as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

    All documents, reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    ITEM 8.

    EXHIBITS.

     

    Exhibit
    Number
      

    Description

     4.1    Fourth Amended and Restated Certificate of Incorporation, as amended through June  20, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No.  001-38537), filed with the Commission on August 14, 2024).
     4.2    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 25, 2018).
     5.1    Opinion of Cooley LLP.
    23.1    Consent of Deloitte & Touche LLP, independent registered public accounting firm of Tectonic Therapeutic, Inc.
    23.2    Consent of Cooley LLP. Reference is made to Exhibit 5.1.

     

    1


    Exhibit
    Number
      

    Description

    24.1    Power of Attorney. Reference is made to the signature page hereto.
    99.1    Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
    99.2    Forms of Option Grant Notice, Option Agreement and Notice of Exercise under Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
    99.3    Tectonic Therapeutic, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
    107    Filing Fee Table.

     

    ITEM 9.

    UNDERTAKINGS.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement; and

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2


    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on March 20, 2025.

     

    TECTONIC THERAPEUTIC, INC.
    By   /s/ Alise Reicin
      Alise Reicin
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alise Reicin and Daniel Lochner, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable Tectonic Therapeutic, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Alise Reicin

    Alise Reicin

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      March 20, 2025

    /s/ Daniel Lochner

    Daniel Lochner

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      March 20, 2025

    /s/ Terrance McGuire

    Terrance McGuire

       Director   March 20, 2025

    /s/ Phillip B. Donenberg

    Phillip B. Donenberg

       Director   March 20, 2025

    /s/ Timothy A. Springer

    Timothy A. Springer

       Director   March 20, 2025

    /s/ Praveen Tipirneni

    Praveen Tipirneni

       Director   March 20, 2025

    /s/ Stefan Vitorovic

    Stefan Vitorovic

       Director   March 20, 2025

     

    4

    Get the next $TECX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    10/20/2025$101.00Overweight
    Wells Fargo
    9/3/2025$80.00Outperform
    Oppenheimer
    7/21/2025$64.00Buy
    Truist
    6/11/2025$76.00Outperform
    Raymond James
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    More analyst ratings

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/11/25 6:12:08 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/9/25 5:38:10 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/7/25 4:21:19 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

    Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $101.00

    10/20/25 8:03:48 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Tectonic Therapeutic with a new price target

    Oppenheimer initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $80.00

    9/3/25 8:39:51 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Tectonic Therapeutic with a new price target

    Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

    7/21/25 8:39:42 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $TECX
    SEC Filings

    View All

    Tectonic Therapeutic to Participate in December Investor Conferences

    WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew York, NYFireside ChatAlise Reicin, MD, President and Chief Executive OfficerLink Evercore 8th Annual Healthcare Conference Date:Location:Format:December 3,

    12/1/25 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

    Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1'2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in patients with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45Ongoing TX45 APEX Phase 2 clinic

    11/6/25 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

    TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH‑HFrEF")TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45's addressable Group 2 PH patient population to PH‑HFrEFCompany to host webcast today, October 29th at 4:30 p.m. ET WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced positive topline results from the Phase 1b Part B acute hemodynami

    10/29/25 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Business Officer Schwabish Marc covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 7% to 21,314 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/10/26 4:10:40 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 2,064 shares, decreasing direct ownership by 4% to 53,247 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/10/26 4:09:21 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Mcnamara Peter covered exercise/tax liability with 1,748 shares, decreasing direct ownership by 4% to 39,131 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/10/26 4:06:21 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

    SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/25 4:17:57 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tectonic Therapeutic Inc.

    10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    11/6/25 4:28:50 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    11/6/25 4:15:50 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Financials

    Live finance-specific insights

    View All

    Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

    TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

    1/30/25 6:30:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

    Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

    11/7/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

    TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

    8/14/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

    SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/24 4:05:11 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/24/24 5:12:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care